as of 12-11-2025 2:13pm EST
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
| Founded: | 2018 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTELVEEN |
| Market Cap: | 1.4B | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $6.75 | Next Earning Date: | 11-12-2025 |
| Revenue: | $3,018,000 | Revenue Growth: | 811.78% |
| Revenue Growth (this year): | 943.83% | Revenue Growth (next year): | -93.26% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how ATAI stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.